vs

Side-by-side financial comparison of Bolt Biotherapeutics, Inc. (BOLT) and Catalyst Bancorp, Inc. (CLST). Click either name above to swap in a different company.

Catalyst Bancorp, Inc. is the larger business by last-quarter revenue ($2.7M vs $2.5M, roughly 1.1× Bolt Biotherapeutics, Inc.). Catalyst Bancorp, Inc. runs the higher net margin — 17.2% vs -265.2%, a 282.4% gap on every dollar of revenue. Over the past eight quarters, Catalyst Bancorp, Inc.'s revenue compounded faster (12.6% CAGR vs -31.2%).

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.

Catalyst Bancorp, Inc. is a U.S.-based financial holding company that operates community banking subsidiaries. It provides a full range of retail and commercial banking products including checking and savings accounts, small business loans, residential mortgages, personal lending, and wealth management services, primarily serving local regional markets across the U.S. with a focus on individual consumers and small business clients.

BOLT vs CLST — Head-to-Head

Bigger by revenue
CLST
CLST
1.1× larger
CLST
$2.7M
$2.5M
BOLT
Higher net margin
CLST
CLST
282.4% more per $
CLST
17.2%
-265.2%
BOLT
Faster 2-yr revenue CAGR
CLST
CLST
Annualised
CLST
12.6%
-31.2%
BOLT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BOLT
BOLT
CLST
CLST
Revenue
$2.5M
$2.7M
Net Profit
$-6.6M
$456.0K
Gross Margin
Operating Margin
-283.4%
20.8%
Net Margin
-265.2%
17.2%
Revenue YoY
1.4%
Net Profit YoY
58.4%
-27.2%
EPS (diluted)
$-9.38
$0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BOLT
BOLT
CLST
CLST
Q4 25
$2.5M
$2.7M
Q3 25
$2.2M
$2.8M
Q2 25
$1.8M
$2.8M
Q1 25
$1.2M
$2.9M
Q4 24
$0
$2.5M
Q3 24
$1.1M
$3.2M
Q2 24
$1.3M
$2.8M
Q1 24
$5.3M
$2.1M
Net Profit
BOLT
BOLT
CLST
CLST
Q4 25
$-6.6M
$456.0K
Q3 25
$-7.1M
$489.0K
Q2 25
$-8.6M
$521.0K
Q1 25
$-11.0M
$586.0K
Q4 24
$-15.9M
$626.0K
Q3 24
$-15.2M
$447.0K
Q2 24
$-21.2M
$527.0K
Q1 24
$-10.8M
$-4.7M
Operating Margin
BOLT
BOLT
CLST
CLST
Q4 25
-283.4%
20.8%
Q3 25
-355.1%
21.7%
Q2 25
-510.5%
22.5%
Q1 25
-991.4%
24.7%
Q4 24
31.2%
Q3 24
-1441.1%
17.6%
Q2 24
-1772.3%
23.0%
Q1 24
-324.1%
-284.6%
Net Margin
BOLT
BOLT
CLST
CLST
Q4 25
-265.2%
17.2%
Q3 25
-329.4%
17.7%
Q2 25
-474.6%
18.5%
Q1 25
-903.4%
20.1%
Q4 24
25.3%
Q3 24
-1330.1%
14.2%
Q2 24
-1662.4%
18.7%
Q1 24
-205.0%
-224.0%
EPS (diluted)
BOLT
BOLT
CLST
CLST
Q4 25
$-9.38
$0.13
Q3 25
$-3.72
$0.13
Q2 25
$-4.46
$0.14
Q1 25
$-0.29
$0.16
Q4 24
$-13.73
$0.13
Q3 24
$-7.93
$0.11
Q2 24
$-11.12
$0.13
Q1 24
$-0.28
$-1.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BOLT
BOLT
CLST
CLST
Cash + ST InvestmentsLiquidity on hand
$27.5M
$25.2M
Total DebtLower is stronger
$14.7M
Stockholders' EquityBook value
$26.5M
$81.7M
Total Assets
$56.7M
$282.9M
Debt / EquityLower = less leverage
0.18×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BOLT
BOLT
CLST
CLST
Q4 25
$27.5M
$25.2M
Q3 25
$31.9M
$37.3M
Q2 25
$34.8M
$40.1M
Q1 25
$38.8M
$40.3M
Q4 24
$47.3M
$44.3M
Q3 24
$53.8M
$45.8M
Q2 24
$73.7M
$75.5M
Q1 24
$91.3M
$76.0M
Total Debt
BOLT
BOLT
CLST
CLST
Q4 25
$14.7M
Q3 25
$14.7M
Q2 25
Q1 25
Q4 24
$9.6M
Q3 24
$29.5M
Q2 24
$30.3M
Q1 24
$29.4M
Stockholders' Equity
BOLT
BOLT
CLST
CLST
Q4 25
$26.5M
$81.7M
Q3 25
$32.1M
$81.6M
Q2 25
$38.8M
$80.8M
Q1 25
$46.8M
$80.6M
Q4 24
$57.2M
$80.2M
Q3 24
$72.0M
$81.7M
Q2 24
$85.9M
$81.0M
Q1 24
$104.2M
$81.3M
Total Assets
BOLT
BOLT
CLST
CLST
Q4 25
$56.7M
$282.9M
Q3 25
$65.1M
$283.8M
Q2 25
$75.5M
$273.8M
Q1 25
$85.9M
$271.6M
Q4 24
$99.6M
$276.7M
Q3 24
$109.3M
$280.6M
Q2 24
$124.2M
$295.3M
Q1 24
$142.9M
$282.0M
Debt / Equity
BOLT
BOLT
CLST
CLST
Q4 25
0.18×
Q3 25
0.18×
Q2 25
Q1 25
Q4 24
0.12×
Q3 24
0.36×
Q2 24
0.37×
Q1 24
0.36×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BOLT
BOLT
CLST
CLST
Operating Cash FlowLast quarter
$-7.2M
$3.3M
Free Cash FlowOCF − Capex
$3.1M
FCF MarginFCF / Revenue
116.8%
Capex IntensityCapex / Revenue
7.1%
Cash ConversionOCF / Net Profit
7.21×
TTM Free Cash FlowTrailing 4 quarters
$5.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BOLT
BOLT
CLST
CLST
Q4 25
$-7.2M
$3.3M
Q3 25
$-9.7M
$912.0K
Q2 25
$-9.6M
$1.2M
Q1 25
$-13.4M
$427.0K
Q4 24
$-14.4M
$3.2M
Q3 24
$-14.0M
$896.0K
Q2 24
$-16.1M
$1.4M
Q1 24
$-16.8M
$247.0K
Free Cash Flow
BOLT
BOLT
CLST
CLST
Q4 25
$3.1M
Q3 25
$827.0K
Q2 25
$1.1M
Q1 25
$361.0K
Q4 24
$2.7M
Q3 24
$-14.0M
$771.0K
Q2 24
$1.2M
Q1 24
$223.0K
FCF Margin
BOLT
BOLT
CLST
CLST
Q4 25
116.8%
Q3 25
29.9%
Q2 25
39.7%
Q1 25
12.4%
Q4 24
110.9%
Q3 24
-1227.6%
24.5%
Q2 24
41.5%
Q1 24
10.7%
Capex Intensity
BOLT
BOLT
CLST
CLST
Q4 25
7.1%
Q3 25
3.1%
Q2 25
1.2%
Q1 25
2.3%
Q4 24
17.4%
Q3 24
3.6%
4.0%
Q2 24
0.0%
8.0%
Q1 24
0.0%
1.1%
Cash Conversion
BOLT
BOLT
CLST
CLST
Q4 25
7.21×
Q3 25
1.87×
Q2 25
2.21×
Q1 25
0.73×
Q4 24
5.07×
Q3 24
2.00×
Q2 24
2.64×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons